New pipeline boosts Sanofi-Aventis (SNY)

by Paul Tracy, editor High Yield International

Last year, Paris-based pharmaceutical giant Sanofi-Aventis (SNY) faced a problem many large pharmaceutical firms have encountered in recent years: a raft of major patent expirations.

Now, however, growth from Sanofi's pipeline of new drugs is beginning to power growth.